Rhabdomyosarcoma: Current challenges and their implications for developing therapies

Cold Spring Harbor Perspectives in Medicine

Volumn 4, Issue 11, 2014, Pages

  Hettmer, Simone ^a   Li, Zhizhong ^a   Billin, Andrew N ^a   Barr, Frederic G ^a   Cornelison, D ^a   Ehrlich, Alan R ^a   Guttridge, Denis C ^a   Hayes Jordan, Andrea ^a   Helman, Lee J ^a   Houghton, Peter J ^a   Khan, Javed ^a   Langenau, David M ^a   Linardic, Corinne M ^a   Pal, Ranadip ^a   Partridge, Terence A ^a   Pavlath, Grace K ^a   Rota, Rossella ^a   Schafer, Beat W ^a   Shipley, Janet ^a   Stillman, Bruce ^a   Wexler, Leonard H ^a   Wagers, Amy J ^a   Keller, Charles ^a   more..

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSTATIC AGENT; TEMSIROLIMUS; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR PAX3; TRANSCRIPTION FACTOR PAX7;

ARTICLE; CELL FUNCTION; CHILDHOOD CANCER; CHROMOSOME TRANSLOCATION; CLONAL EVOLUTION; CYTOLOGY; DISEASE COURSE; DNA METHYLATION; DRUG EFFECT; EVENT FREE SURVIVAL; GENETIC VARIABILITY; GERMLINE MUTATION; HIGH RISK PATIENT; HIGH THROUGHPUT SCREENING; HUMAN; MAINTENANCE THERAPY; OVERALL SURVIVAL; PHENOTYPE; POTENTIAL DIFFERENCE; PREVALENCE; PRIMARY TUMOR; PROTEIN FUNCTION; RHABDOMYOSARCOMA; SOFT TISSUE SARCOMA; TRANSACTIVATION; TREATMENT FAILURE; TUMOR BIOPSY; TUMOR MICROENVIRONMENT; ADOLESCENT; ADULT; AGE; CHILD; GENETICS; MUSCLE NEOPLASMS; PUBLIC RELATIONS; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; CHILD; HUMANS; INTERINSTITUTIONAL RELATIONS; MUSCLE NEOPLASMS; RHABDOMYOSARCOMA; YOUNG ADULT;

EID: 84908425477     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a025650     Document Type: Article

References (41)

1. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehar J, Kryukov GV, Sonkin D, et al. 2012. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483: 603-607.
2. Chen EY, Dobrinski KP, Brown KH, Clagg R, Edelman E, Ignatius MS, Chen JY, Brockmann J, Nielsen GP, Ramaswamy S, et al. 2013. Cross-species array comparative genomic hybridization identifies novel oncogenic events in zebrafish and human embryonal rhabdomyosarcoma. PLoS Genet 9: e1003727.
3. Ciarapica R, De Salvo M, Carcarino E, Bracaglia G, Adesso L, Leoncini PP, Dall’agnese A, Walters ZS, Verginelli F, De Sio L, et al. 2013. The Polycomb group (PcG) protein EZH2 supports the survival of PAX3-FOXO1 alveolar rhabdomyosarcoma by repressing FBXO32 (Atrogin1/MAFbx). Oncogene 33: 4173-4184.
4. Coffin CM, Rulon J, Smith L, Bruggers C, White FV. 1997. Pathologic features of rhabdomyosarcoma before and after treatment: A clinicopathologic and immunohistochemical analysis. Mod Pathol 10: 1175-1187.
5. Dagher R, Helman L. 1999. Rhabdomyosarcoma: An overview. Oncologist 4: 34-44.
6. Egas-Bejar D, Huh WD. 2014. Rhabdomyosarcoma in adolescent and young adult patients: Current perspectives. Adolesc Health Med Ther 5: 115-125.
7. Geoerger B, Kieran MW, Grupp S, Perek D, Clancy J, Krygowski M, Ananthakrishnan R, Boni JP, Berkenblit A, Spunt SL. 2012. Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma. Eur J Cancer 48: 253-262.
8. Hatley ME, Tang W, Garcia MR, Finkelstein D, Millay DP, Liu N, Graff J, Galindo RL, Olson EN. 2012. A mouse model of rhabdomyosarcoma originating from the adipocyte lineage. Cancer Cell 22: 536-546.
9. Hawkins DS, Spunt SL, Skapek SX. 2013. Children’s Oncology Group’s 2013 blueprint for research: Soft tissue sarcomas. Pediatr Blood Cancer 60: 1001-1008.
10. Hettmer S, Wagers AJ. 2010. Muscling in: Uncovering the origins of rhabdomyosarcoma. Nat Med 16: 171-173.
11. Hettmer S, Liu J, Miller CM, Lindsay MC, Sparks CA, Guertin DA, Bronson RT, Langenau DM, Wagers AJ. 2011. Sarcomas induced in discrete subsets of prospectively isolated skeletal muscle cells. Proc Natl Acad Sci 108: 20002-20007.
12. Hettmer S, Archer NM, Somers GR, Novokmet A, Wagers AJ, Diller L, Rodriguez-Galindo C, Teot LA, Malkin D. 2014. Anaplastic rhabdomyosarcoma in TP53 germline mutation carriers. Cancer 120: 1068-1075.
13. Highfill SL, Cui Y, Giles AJ, Smith JP, Zhang H, Morse E, Kaplan RN, Mackall CL. 2014. Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. Sci Transl Med 6: 237-67.
14. Hosoi H, Dilling MB, Shikata T, Liu LN, Shu L, Ashmun RA, Germain GS, Abraham RT, Houghton PJ. 1999. Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells. Cancer Res 59: 886-894.
15. Ignatius MS, Chen E, Elpek NM, Fuller AZ, Tenente IM, Clagg R, Liu S, Blackburn JS, Linardic CM, Rosenberg AE, et al. 2012. In vivo imaging of tumor-propagating cells, regional tumor heterogeneity, and dynamic cell movements in embryonal rhabdomyosarcoma. Cancer Cell 21: 680-693.
16. Kratz CP, Rapisuwon S, Reed H, Hasle H, Rosenberg PS. 2011. Cancer in Noonan, Costello, cardiofaciocutaneous and LEOPARD syndromes. AmJMed Genet C Semin Med Genet 157C: 83-89.
17. Langenau DM, Keefe MD, Storer NY, Guyon JR, Kutok JL, Le X, Goessling W, Neuberg DS, Kunkel LM, Zon LI. 2007. Effects of RAS on the genesis of embryonal rhabdomyosarcoma. Genes Dev 21: 1382-1395.
18. Mascarenhas L, Meyer BH, Lyden E, Rodeberg DA, Indelicato DJ, Linardic CM, Anderson JR, Hawkins DS. 2014. Randomized phase II trial of bevacizumab and temsirolimus in combination with vinorelbine (V) and cyclophosphamide (C) for first relapse/disease progression of rhabdomyosarcoma (RMS): A report from the Children’s Oncology Group (COG). J Clin Oncol 32 (Suppl): 5s.
19. Mayeenuddin LH, Yu Y, Kang Z, Helman LJ, Cao L. 2010. Insulin-like growth factor 1 receptor antibody induces rhabdomyosarcoma cell death via a process involving AKTand Bcl-x(L). Oncogene 29: 6367-6377.
20. Missiaglia E, Williamson D, Chisholm J, Wirapati P, Pierron G, Petel F, Concordet JP, Thway K, Oberlin O, Pritchard-Jones K, et al. 2012. PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification. J Clin Oncol 30: 1670-1677.
21. Oberlin O, Rey A, Lyden E, Bisogno G, Stevens MC, Meyer WH, Carli M, Anderson JR. 2008. Prognostic factors in metastatic rhabdomyosarcomas: Results of a pooled analysis from United States and European cooperative groups. J Clin Oncol 26: 2384-2389.
22. Pappo AS, Shapiro DN, Crist WM, Maurer HM. 1995. Biology and therapy of pediatric rhabdomyosarcoma. J Clin Oncol 13: 2123-2139.
23. Pappo AS, Vassal G, Crowley JJ, Bolejack V, Hogendoorn PC, Chugh R, Ladanyi M, Grippo JF, Dall G, Staddon AP, et al. 2014. A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patientswith recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: Results of a Sarcoma Alliance for Research Through Collaboration study. Cancer 120: 2448-2456.
24. Parham DM. 2001. Pathologic classification of rhabdomyosarcomas and correlations with molecular studies. Mod Pathol 14: 506-514.
25. Perez EA, Kassira N, Cheung MC, Koniaris LG, Neville HL, Sola JE. 2011. Rhabdomyosarcoma in children: A SEER population based study. J Surg Res 170: e243-e251.
26. Pratt CB, Hustu HO, Fleming ID, Pinkel D. 1972. Coordinated treatment of childhood rhabdomyosarcoma with surgery, radiotherapy, and combination chemotherapy. Cancer Res 32: 606-610.
27. Punyko JA, Mertens AC, Gurney JG, Yasui Y, Donaldson SS, Rodeberg DA, Raney RB, Stovall M, Sklar CA, Robison LL, et al. 2005. Long-term medical effects of childhood and adolescent rhabdomyosarcoma: A report from the childhood cancer survivor study. Pediatr Blood Cancer 44: 643-653.
28. Rubin BP, Nishijo K, Chen HI, Yi X, Schuetze DP, Pal R, Prajapati SI, Abraham J, Arenkiel BR, Chen QR, et al. 2011. Evidence for an unanticipated relationship between undifferentiated pleomorphic sarcoma and embryonal rhabdomyosarcoma. Cancer Cell 19: 177-191.
29. Schneider G, Bowser MJ, Shin DM, Barr FG, Ratajczak MZ. 2014. The paternally imprinted DLK1-GTL2 locus is differentially methylated in embryonal and alveolar rhabdomyosarcomas. Int J Oncol 44: 295-300.
30. Shern JF, Chen L, Chmielecki J, Wei JS, Patidar R, Rosenberg M, Ambrogio L, Auclair D, Wang J, Song YK, et al. 2014. Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. Cancer Discov 4: 216-231.
31. Skapek SX, Anderson J, Barr FG, Bridge JA, Gastier-Foster JM, Parham DM, Rudzinski ER, Triche T, Hawkins DS. 2013. PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: A children’s oncology group report. Pediatr Blood Cancer 60: 1411-1417.
32. Smith LM, Anderson JR, Coffin CM. 2002. Cytodifferentiation and clinical outcome after chemotherapy and radiation therapy for rhabdomyosarcoma (RMS). Med Pediatr Oncol 38: 398-404.
33. Sokolowski E, Turina CB, Kikuchi K, Langenau DM, Keller C. 2014. Proof-of-concept rare cancers in drug development: The case for rhabdomyosarcoma. Oncogene 33: 1877-1889.
34. Sorensen PH, Lynch JC, Qualman SJ, Tirabosco R, Lim JF, Maurer HM, Bridge JA, Crist WM, Triche TJ, Barr FG. 2002. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: A report from the children’s oncology group. J Clin Oncol 20: 2672-2679.
35. Sultan I, Qaddoumi I, Yaser S, Rodriguez-Galindo C, Ferrari A. 2009. Comparing adult and pediatric rhabdomyosarcoma in the surveillance, epidemiology and end results program, 1973 to 2005: An analysis of 2,600 patients. J Clin Oncol 27: 3391-3397.
36. Walter D, Satheesha S, Albrecht P, Bornhauser BC, D’Alessandro V, Oesch SM, Rehrauer H, Leuschner I, Koscielniak E, Gengler C, et al. 2011. CD133 positive embryonal rhabdomyosarcoma stem-like cell population is enriched in rhabdospheres. PLoS ONE 6: e19506.
37. Walters ZS, Villarejo-Balcells B, Olmos D, Buist TW, Missiaglia E, Allen R, Al-Lazikani B, Garrett MD, Blagg J, Shipley J. 2014. JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells. Oncogene 33: 1148-1157.
38. Weigel B, Malempati S, Reid JM, Voss SD, Cho SY, Chen HX, Krailo M, Villaluna D, Adamson PC, Blaney SM. 2014. Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the Children’s Oncology Group. Pediatr Blood Cancer 61: 452-456.
39. Wharam MD, Meza J, Anderson J, Breneman JC, Donaldson SS, Fitzgerald TJ, Michalski J, Teot LA, Wiener ES, Meyer WH. 2004. Failure pattern and factors predictive of local failure in rhabdomyosarcoma: A report of group III patients on the third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 22: 1902-1908.
40. Williamson D, Missiaglia E, de Reynies A, Pierron G, Thuille B, Palenzuela G, Thway K, Orbach D, Lae M, Freneaux P, et al. 2010. Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. J Clin Oncol 28: 2151-2158.
41. Xia SJ, Pressey JG, Barr FG. 2002.Molecular pathogenesis of rhabdomyosarcoma. Cancer Biol Ther 1: 97-104.